Form 4: Baker Bros. Advisors Report Changes in Beneficial Ownership of Incyte Corp (INCY)

Baker Bros. Advisors LP reports changes in beneficial ownership of Incyte Corp stock due to director retainer fees and indirect ownership interests.

Summary

• Baker Bros. Advisors LP filed a Form 4 detailing changes in beneficial ownership of Incyte Corp (INCY) common stock.
• The filing reports the acquisition of 543 shares of common stock by Julian C. Baker on March 28, 2024, in lieu of quarterly director retainer fees of $32,000.
• The shares were issued under Incyte's Amended and Restated 2010 Stock Incentive Plan and are fully vested.
• The filing also reflects adjustments to the reported holdings of various Baker Bros. entities due to their indirect ownership interests.
• Julian C. Baker and Felix J. Baker may be deemed to have indirect pecuniary interests in shares held by 667, L.P. and Baker Brothers Life Sciences, L.P.
• After the reported transactions, Baker Bros. Advisors LP beneficially owns 2,970,073 shares through Baker Biotech Capital, L.P. and 33,447,981 shares through Baker Brothers Life Sciences, L.P.
• Julian C. Baker directly holds 278,773 shares, and Felix J. Baker directly holds 281,190 shares.
• Additionally, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in 33,410 shares of Common Stock directly held by FBB Associates.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing is a routine disclosure of insider transactions and does not contain any information that would significantly impact investor sentiment.

Positives

• The acquisition of shares by Julian C. Baker demonstrates continued alignment of interests between the director and the company.
• The filing indicates a substantial beneficial ownership stake in Incyte Corp by Baker Bros. Advisors LP, reflecting their confidence in the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their transactions and holdings.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for company insiders, including directors and officers, as well as beneficial owners holding more than 10% of a company's stock.
• The information disclosed in Form 4 filings is used by investors to assess the sentiment and actions of company insiders, which can provide insights into the company's prospects.
• Comparable companies in the biotechnology industry, such as Amgen, Gilead Sciences, and Biogen, also have frequent Form 4 filings related to insider transactions.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership stake of Baker Bros. Advisors LP in Incyte Corp.
• The acquisition of shares by Julian C. Baker in lieu of director retainer fees aligns his interests with those of shareholders.

Key Dates